Therefore, combination of a-Galcer with Tim-3 blockade might be a promising approach in chronic hepatitis B therapy.
activated by a-Galcer, a glycolipid from marine sponge. 7, 8 iNKT cells, on activation, can produce both Th1 cytokines such as IFN-c and Th2 cytokines such as IL-4/IL-13 within a few hours, the intensity and magnitude of which are closely related to various disease outcome such as cancer and infection. [9] [10] [11] [12] Increasing evidence suggests that iNKT cells play a key role in anti-HBV immunity. [13] [14] [15] In a clinical research, the per cent of peripheral iNKT cells was decreased in patients with CHB, but antiviral treatment increased their frequencies, 16, 17 which meant that iNKT cells might be linked to CHB development. The underlying mechanisms of iNKT cell involving in antiviral immune responses are further demonstrated by employing HBV mouse models, which showed that iNKT cells contributed to the priming of antiviral B and T cell immunity. 5 a-Galcer could promote the induction and proliferation of HBV-specific cytotoxic T lymphocytes (CTLs). 18 Moreover, a-Galcer was proved to inhibit HBV replication by directly activating iNKT cells and by secondarily activating natural killer (NK) cells to secrete antiviral IFN-c or IFN-a/ b. 13 Therefore, improving iNKT cell function using a-Galcer seems a feasible strategy for clinical practice of curing patients with CHB.
However, a-Galcer used as a monotherapy resulted in an obvious decrease in iNKT cell number in patients with CHB and did not clearly affect HBV DNA level. 19 Recent work from Shi laboratory showed that activating CD28/CD80 signal or blocking of programmed death (PD)-1/PD-L1, combined with a-Galcer in HBV-Tg mouse, had obtained a better control of HBV replication, 20 strongly suggested that immune checkpoints might be new targets to reinforce iNKT cell function to inhibit HBV replication.
As a well-known immune checkpoint, Tim-3 has been widely studied in a variety of immune cells, including Th1 cells, CTLs and NK cells. 21, 22 In these cells, Tim-3 has been described of playing roles in the regulation of cell apoptosis, proliferation, cytotoxicity and cytokine production. which indicating a possible relation between Tim-3 and disease development. As to the regulation of Tim-3 on iNKT cells, current researches showed that activating Tim-3 pathway by binding to its ligand, galectin-9 (Gal-9), affected apoptosis of iNKT cells in various models. [25] [26] [27] In the condition of CHB, published data reported a higher expression of Tim-3 on peripheral NKT cells in patients with CHB, 28 but the possible role of Tim-3-NKT axis in HBV control is still largely unknown.
Here, we studied the role of Tim-3 on regulating iNKT cells in a-
Galcer-induced acute hepatitis model in the background of HBs-Tg C57BL/6 mice or HBV-Tg Balb/c mice. Data showed that CD3 + CD1d + iNKT cells were activated by a-Galcer with an increased Tim-3 expression, which was consistent with previous reports.
Blocking Tim-3 pathway with anti-Tim-3 neutralizing antibodies greatly promoted the ability of iNKT cells to produce cytokines and cytotoxic granules, which indicated a negative regulatory role of Tim-3 on iNKT cells. This role was confirmed in Tim-3 KO mice.
Furthermore, Tim-3 blockade significantly enhanced the HBV suppression induced by a-Galcer. This may shed a light on future studies of iNKT cell and Tim-3/iNKT cell-based HBV immunotherapy. 
| MATERIALS AND METHODS

| Preparation of intrahepatic lymphocytes
Intrahepatic lymphocytes (IHLs) were separated for functional testing. Briefly, mice livers were harvested, teased apart and mashed through a nylon mesh to get primary cell suspension. After lysing red blood cells in the suspension, IHLs were obtained by centrifugation over 40% Percoll solution (GE Healthcare, Uppsala, Sweden). 
| Tim-3 blocking assay
Tim-3 in vivo blockade was performed by intraperitoneal (i.p.) injection of 100 lg of aTim-3 (eBioscience) 24 hours before administration of a-Galcer. For another 24 hours, mice were killed for experiments.
For blocking Tim-3 pathway in iNKT cells, IHLs were pre-incubated with 5 lg of anti-Tim-3 antibodies (eBioscience) for 30 minutes and then stimulated with a-Galcer (1 lg/mL) for another 6 hours. BFA was added 4 hours before cell harvest. 
| a-Galcer stimulation
| Statistical analysis
Statistical analysis was performed with the paired or unpaired Student's t test using the GraphPad Prism 5 software. For all tests, P ⩽ .05 ( * ), P ⩽ .01 ( * * ) or P ⩽ .001 ( * * * ) was considered as significant.
3 | RESULTS
| Tim-3 expression is up-regulated on iNKT cells in HBV-Tg mice and correlated with iNKT cell activation
To investigate the role of Tim-3 in iNKT cells in CHB, we firstly detected the expression of Tim-3 on iNKT cells in HBV-Tg mice. 
| Tim-3 blockade augments a-Galcer-induced inhibition on HBV replication
It has been previously reported that a-Galcer inhibits HBV replication in HBV-Tg mice. 13 To address whether Tim-3 promotes a-Gal-
cer-initiated HBV inhibition, HBV-Tg mice were treated with a-
Galcer alone (a-Galcer +IgG) or a-Galcer combined with anti-Tim-3
(a-Galcer+aTim-3). As expected, comparing with control group, mice from the group of a-Galcer+aTim-3 showed larger areas of necrosis in the liver ( Figure 5A ). Accordingly, serum ALT level was also higher in mice treated with a-Galcer plus anti-Tim-3 (
Figure 5B Figure S1 ) showed that blocking Tim-3 pathway inhibited pgRNA expression in HBV-Tg mice ( Figure 5D ). Taken together, our data demonstrated that Tim-3 blockade significantly enhances a-Galcer-mediated inhibition of HBV replication in vivo.
| Tim-3 blockade also promotes iNKT cell function to inhibit HBsAg secretion in HBs-Tg mice
To exclude the potential species specificity in Tim-3 blockade promoted enhancement of iNKT cells and HBV inhibition, similar experiments were carried on in HBs-Tg C57BL/6 mice. As shown in Figure 6A , after treatment with a-Galcer, serum HBsAg level was largely decreased, and Tim- iNKT and Tim-3-iNKT cells. Data were analysed using paired or unpaired Student's t test. For all graphs: P < .05 ( * ), P < .01 ( * * ) or P < .001 ( * * * ) was considered as significant XU ET AL. from HBV-Tg mice were pre-incubated with 5 lg/mL of anti-Tim-3(aTim-3) or IgG antibodies for 30 minutes and then stimulated with 1 lg/ mL a-Galcer for 6 h. The expression of IFN-c and CD107a in iNKT cells was compared (E and F). All data were analysed using paired or unpaired Student's t test. For all graphs: ns (no significance), P < .05 ( * ), P < .01 ( * * ) or P < .001 ( * * * )
indicating damaged immune response, and blocking Tim-3 pathway partly restored T/NK cells function. 34, 35 Therefore, Tim-3 was considered as an important checkpoint in disease development. Our work here highlights the potential of Tim-3 blockade in immunotherapy not only for enhancing CD8 + T/NK cells but also for iNKT cells.
F I G U R E 3 a-Galcer promoted iNKT cell function in Tim-3 KO mice. 2 lg of a-Galcer was i.p. injected into Tim-3 KO mice or control mice; 2 h later, these mice were killed and IHLs were separated. Functional tests showed that the production of IFN-c, TNF-a and CD107a of iNKT cells was much higher in Tim-3 KO mice (A and B) (n = 3). P < .05 ( * ) to IFN-c becomes the most powerful forces against HBV replication. 13 Even though NK/CD8 T cells will take the place of F I G U R E 5 Tim-3 blockade augmented a-Galcer-induced HBV inhibition. Acute hepatitis was induced in HBV-Tg mice with 2 lg of aGalcer, and liver tissues were taken and stained with H and E at 24 h after treatment of a-Galcer (A). Serum ALT (B), IFN-c, TNF-a (C) and HBsAg (E) were detected and quantified by ELISA kits and compared with the level of pre-treatment of a-Galcer (n = 3). Serum HBV DNA copies (F) and the expression of pgRNA in liver tissues were detected by qPCR (D) (n = 3). All data were analysed using unpaired Student's t test. For all graphs: P < .05 ( * ) overactivated iNKT cells, a randomized placebo-controlled trial still failed to detect the success inhibition of HBV DNA in a-Galcer-treated patients with CHB, which we had to attribute this failure to the poor tolerance of a-Galcer or the obvious drop of iNKT cell number. 19 Constantly, we found a-Galcer largely reduced the percentage of hepatic iNKT cells as well as the cell number in the mice models. . All data were analysed using unpaired Student's t test. For all graphs: ns (no significance), P < .05 ( * ), P < .01 ( * * ) or P < .001 ( * * * ) XU ET AL.
| 3199
But Tim-3 blockade promoted IFN-c or CD107a production from CD8 + T cells or NK cells and could also regulate NK cell frequency. 13 It seems that the role of aTim-3 promoting NK cells was independent of a-Galcer, for we observed partly up-regulated NK cell function in control group, the reason of which may be related to the mild inflammatory environment in liver tissues caused by control vehicle. Besides, another fact is that a-Galcer-induced HBV inhibition was abolished if iNKT cells were eliminated 13 ; hence, we noticed 
